0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-1

PD-1

PD-1 Molecule Information

Name:Programmed cell death protein 1
Target Synonym:Programmed cell death protein 1?CD279?hPD-1?PDCD1?Programmed Cell Death 1?Systemic Lupus Erythematosus Susceptibility 2?Protein PD-1?PD1?Programmed Cell Death 1 Protein?CD279 Antigen?HPD-L?HSLE1?SLEB2?PD-1?Programmed Cell Death 1 Receptor
Number of Launched Drugs:8
Number of Drugs in Clinical Trials:73
Lastest Research Phase:Approved

PD-1 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
PD1-H52H6 Human Human PD-1 / PDCD1 Full Length Protein, His Tag
PD1-H52H6-structure
PD1-H52H6-sds
PD1-H52H6-elisa_1
PD1-H82F4 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F4-structure
PD1-H82F4-sds
PD1-H82F4-hplc
PD1-H82F4-elisa_1
PD1-C82E6 Cynomolgus Biotinylated Cynomolgus PD-1 / PDCD1 Protein, His,Avitag™
PD1-C82E6-structure
PD1-C82E6-sds
PD1-C82E6-elisa_1
PD1-HP2F2 Human PE-Labeled Human PD-1 / PDCD1 Protein, Fc Tag, His Tag (recommended for neutralizing assay)
PD1-HP2F2-structure
PD1-H5255 Human Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (HPLC-verified)
PD1-H5255-structure
PD1-H5255-sds
PD1-H5255-hplc
PD1-H5255-elisa_1
PD1-H522a Human Human PD-1 / PDCD1 Protein, His Tag, low endotoxin (MALS verified)
PD1-H522a-structure
PD1-H522a-sds
PD1-H522a-hplc
PD1-H522a-elisa_1
EPC-V1 Monkey ELISA Assay Kit for Anti-PD-1 h-mAb in Monkey Serum
EPC-V1-elisa_1
EPM-V1 Mouse ELISA Assay Kit for Anti-PD-1 h-mAb in Mouse Serum
EPM-V1-elisa_1
PD1-H5259 Human Human PD-1 / PDCD1 Protein, Llama IgG2b Fc Tag, low endotoxin
PD1-H5259-structure
PD1-H5259-sds
PD1-H5259-elisa_1
EPH-V1 Human ELISA Assay Kit for Anti-PD-1 h-mAb in Human Serum
EPH-V1-elisa_1
PD1-H82F1 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified)
PD1-H82F1-structure
PD1-H82F1-sds
PD1-H82F1-elisa_1
PD1-RB5251 Rabbit Rabbit PD-1 / PDCD1 Protein, Fc Tag
PD1-RB5251-structure
PD1-RB5251-sds
PD1-RB5251-elisa_1
PD1-M52A4 Mouse Mouse PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag
PD1-M52A4-structure
PD1-M52A4-sds
PD1-M52A4-elisa_1
PD1-R52H2 Rat Rat PD-1 / PDCD1 Protein, His Tag
PD1-R52H2-structure
PD1-R52H2-sds
PD1-R52H2-elisa_1
PD1-H82E4 Human Biotinylated Human PD-1 / PDCD1 Protein, Avitag™,His Tag (recommended for biopanning) (MALS verified)
PD1-H82E4-structure
PD1-H82E4-sds
PD1-H82E4-elisa_1
PD1-R52H0 Rabbit Rabbit PD-1 / PDCD1 Protein, His Tag
PD1-R52H0-structure
PD1-R52H0-sds
PD1-M82F4 Mouse Biotinylated Mouse PD-1 / PDCD1 Protein, Fc,Avitag™
PD1-M82F4-structure
PD1-M82F4-sds
PD1-M82F4-elisa_1
PD1-R5253 Rat Rat PD-1 / PDCD1 Protein, Fc Tag
PD1-R5253-structure
PD1-R5253-sds
PD1-R5253-elisa_1
PD1-M5259 Mouse Mouse PD-1 / PDCD1 Protein, Fc Tag
PD1-M5259-structure
PD1-M5259-sds
PD1-M5259-elisa_1
PD1-M5259-elisa_2
PD1-H5284 Human Human PD-1 / PDCD1 Protein, Strep Tag
PD1-H5284-structure
PD1-H5284-sds
PD1-H5284-elisa_1
PD1-H82F2 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™,His Tag
PD1-H82F2-structure
PD1-H82F2-sds
PD1-H82F2-elisa_1
PD1-M5228 Mouse Mouse PD-1 / PDCD1 Protein, His Tag
PD1-M5228-structure
PD1-M5228-sds
PD1-C5254 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, Fc Tag
PD1-C5254-structure
PD1-C5254-sds
PD1-C5254-elisa_1
PD1-C5223 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, His Tag
PD1-C5223-structure
PD1-C5223-sds
PD1-C5223-elisa_1
PD1-C5223-elisa_2
PD1-H5257 Human Human PD-1 / PDCD1 Protein, Fc Tag, low endotoxin (MALS Verified)
PD1-H5257-structure
PD1-H5257-sds
PD1-H5257-hplc
PD1-H5257-elisa_1
PD1-H5257-elisa_2
PD1-H5221 Human Human PD-1 / PDCD1 Protein, His Tag (MALS Verified)
PD1-H5221-structure
PD1-H5221-sds
PD1-H5221-hplc
PD1-H5221-elisa_1
PD1-H5221-elisa_2

PD-1 Part of Bioactivity data

PD1-HP2F2-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μl stock solution per million cells (QC tested).

PD1-HP2F2-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) to 293T overexpressing PD-L1 was inhibited by increasing concentration of neutralizing anti- human PD-L1 antibody. The  IC50 is 0.29 μg/ml (QC tested).

PD1-M5259-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

PD1-M5259-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-L1, His Tag (Cat. No. PD1-M5220) on CM5 Chip via Anti-His antibody can bind Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) with an affinity constant of 1.37 μM as determined in SPR assay (Biacore T200) (Routinely tested).

PD-1 Customer Reviews

PD-1 Molecule Synonym Name

PDCD1,PD1,CD279,SLEB2

PD-1 Molecule Background

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

PD-1 References

PD-1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Prolgolimab BCD-100 Approved Biocad Forteca Russian Federation Melanoma s:6:"Biocad"; 2020-04-01 Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms Details
Camrelizumab SHR-1210; INCSHR-1210; HR-301210 Approved Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd 艾立妥, 艾瑞卡 Mainland China Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung s:41:"Suzhou Suncadia Biopharmaceuticals Co Ltd"; 2019-05-29 Lymphoma, Extranodal NK-T-Cell; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Respiratory Tract Neoplasms; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Breast Neoplasms; Lung Diseases; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Carcinoma, Renal Cell; Bronchial Neoplasms; Thoracic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Carcinoma, Bronchogenic Details
Tislelizumab BGB-A317 Approved Beigene Ltd 百泽安 Mainland China Carcinoma, Transitional Cell s:11:"Beigene Ltd"; 2019-12-26 Breast Neoplasms; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Squamous Cell; Lymphoma, T-Cell; Esophageal Squamous Cell Carcinoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Microsatellite Instability; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Hodgkin Disease; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours Details
Toripalimab JS-001; SO-001; TAB-001 Approved Shanghai Junshi Biosciences Co Ltd, Suzhou Union Biopharm Biosciences Co Ltd 拓益 Mainland China Melanoma s:34:"Shanghai Junshi Biosciences Co Ltd"; 2018-12-17 Solid tumours; Kidney Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Nivolumab MDX-1106; ONO-4538; ono-0123; BMS-936558; BMS-936558-01 Approved Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd 欧狄沃, Opdivo EU Esophageal Squamous Cell Carcinoma s:32:"Bristol-Myers Squibb Pharma Eeig"; 2014-07-04 Esophageal Squamous Cell Carcinoma; Mesothelioma; Multiple Myeloma; Breast Neoplasms; Microsatellite Instability; Sarcoma; Cholangiocarcinoma; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Diarrhea; Colorectal Neoplasms; Peritoneal Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Hepatitis C; Prostatic Neoplasms, Castration-Resistant; Glioma; Lymphoma; Carcinoma, Squamous Cell; Lung Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Urogenital Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Irritable Bowel Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Bone Marrow Neoplasms; Solid tumours; Chondrosarcoma; Lymphoma, B-Cell; Kidney Neoplasms; Liver Neoplasms; Carcinoma, Merkel Cell; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Details
Sintilimab IBI-308 Approved Innovent Biologics(Suzhou) Co Ltd 达伯舒, Tyvyt Mainland China Hodgkin Disease s:33:"Innovent Biologics(Suzhou) Co Ltd"; 2018-12-24 Solid tumours; Esophageal Neoplasms; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Colorectal Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms Details
Cemiplimab REGN-2810; SAR-439684 Approved Regeneron Pharmaceuticals Inc Libtayo EU Carcinoma, Squamous Cell s:20:"Regeneron Ireland Uc"; 2018-09-28 Peritoneal Neoplasms; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Glioma; Lymphoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Ovarian Neoplasms; Diffuse Intrinsic Pontine Glioma; Hepatitis B; Prostatic Neoplasms; Hodgkin Disease; Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Solid tumours Details
Pembrolizumab h409A11; MK-3475; SCH-900475 Approved Merck & Co Inc 可瑞达, Keytruda United States Triple Negative Breast Neoplasms s:14:"Merck & Co Inc"; 2014-09-04 Urinary Bladder Diseases; Breast Diseases; Neoplasms, Nerve Tissue; Gliosarcoma; Urologic Neoplasms; Bile Duct Neoplasms; Parotid Neoplasms; Thymus Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Neurofibrosarcoma; Respiratory Tract Neoplasms; Sarcoma; Esophageal adenocarcinoma; Vulvar Neoplasms; Primary mediastinal B cell lymphoma; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Microsatellite Instability; Brain Neoplasms; Lymphoma, Follicular; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Thyroid Neoplasms; Carcinoma, Endometrioid; Gastrointestinal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Leukemia, Myeloid, Acute; Esophageal Squamous Cell Carcinoma; Liposarcoma; Epstein-Barr Virus Infections; Carcinoma, Small Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Carcin Details

PD-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Shattuck Labs Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
INSIX RA (Indus Biotech) Clinical Indus Biotech Pvt Ltd Arthritis, Rheumatoid; Inflammation Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
PD-1 knockout engineered T cells (Chengdu MedGenCell) Phase 2 Clinical West China Hospital Of Sichuan University, Chengdu Medgencell Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
RB-0004 RB-0004 Phase 1 Clinical Reyoung Pharmaceutical Co Ltd Solid tumours; Lymphoma Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
HX-009 HX-009 Phase 1 Clinical Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd Liver Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) SG-001 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Lymphoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Breast Neoplasms; Carcinoma, Hepatocellular Details
MAX-10181 MAX-1; MAX-10181 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Neoplasms Details
CX-188 Phase 1 Clinical Cytomx Therapeutics Neoplasms Details
XmAb-23104 (Xencor) Phase 1 Clinical Xencor Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Phase 3 Clinical Bristol-Myers Squibb Company Stomach Neoplasms; Melanoma Details
Sym-021 Sym-021 Phase 1 Clinical Symphogen Lymphoma; Neoplasm Metastasis Details
MGD-019 (MacroGenics) MGD-019 Phase 1 Clinical Macrogenics Colorectal Neoplasms Details
Budigalimab ABBV-181 Phase 1 Clinical Abbvie Inc Ovarian Neoplasms; Head and Neck Neoplasms; HIV Infections; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) Phase 2 Clinical Anhui Kedgene Biotechnology, Hangzhou Cancer Hospital Esophageal Neoplasms Details
W0180 Phase 1 Clinical Pierre Fabre Medicament Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) BAT-1306 Phase 2 Clinical Bio-Thera Solutions Ltd Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) Phase 1 Clinical Anhui Anke Biotechnology (Group)Co Ltd Esophageal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms Details
RO-7247669 RO-7247669 Phase 1 Clinical F. Hoffmann-La Roche Ltd Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
LZM-009 LZM-009 Phase 2 Clinical Livzon(Group) Pharmaceutical Factory Thymoma; Carcinoma, Non-Small-Cell Lung Details
Programmed cell death 1 antibody (Sun Yat-sen University) Phase 2 Clinical Sun Yat-Sen University Carcinoma, Hepatocellular Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) Phase 1 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Solid tumours Details
PD-1 knockout EBV-CTL (Nanjing Medical University) Phase 2 Clinical Nanjing Medical University Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma Details
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) Phase 2 Clinical Chongqing Xinqiao Hospital Squamous Cell Carcinoma of Head and Neck Details
IBI315 IBI315; IBI-315 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd, Hanmi Pharmaceutical Co Ltd Neoplasms Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
ONO-4685 ONO-4685 Phase 1 Clinical Merus Autoimmune Diseases Details
T3011疱疹病毒(深圳市亦诺微医药) Phase 1 Clinical Shenzhen Yinuowei Pharmaceutical Technology Co Ltd Head and Neck Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shandong Xinshidai Pharmaceutical) Phase 2 Clinical Shandong New Time Pharmaceutical Co Ltd Lymphoma, T-Cell, Peripheral; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms Details
MEDI-5752 MEDI-5752 Phase 1 Clinical Medimmune Llc Carcinoma, Renal Cell; Neoplasms Details
YBL-006 YBL-006; YBL 006 Phase 1 Clinical Solid tumours; Neoplasms Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
Recombinant human PD-1 antibody herpes simplex virus Phase 1 Clinical Yangshengtang Co Ltd, Xiamen University Liver Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Melanoma Details
BCD-217 BCD-217 Phase 2 Clinical Biocad Melanoma Details
PD-1 knockout engineered T cells (Cell Biotech) Phase 1 Clinical Cell Biotech Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Sinocelltech) SCT-I10A Phase 3 Clinical Shenzhou Cell Engineering Co Ltd Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular Details
IMU-201 IMU-201 Phase 1 Clinical Imugene Carcinoma, Non-Small-Cell Lung Details
609-A (SBio) 609-A Phase 1 Clinical Shenyang Sunshine Pharmaceutical Co Ltd Neoplasms Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) Phase 1 Clinical Shanxiweiqidaguangming Pharmaceutical Co Ltd Solid tumours Details
XmAb20717 XmAb-20717 Phase 1 Clinical Xencor Astrocytoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Thymoma; Colorectal Neoplasms; Carcinoma, Renal Cell; Prostatic Neoplasms; Vulvar Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Mesothelioma; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University) Phase 2 Clinical Radboud University Nijmegen Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
TY-101 TY-101; TY101 Phase 2 Clinical Tayu Huaxia Biotech Medical Group Co Ltd Solid tumours; Neoplasms; Lymphoma Details
RO-7121661 RG-7769; RO-7121661 Phase 1 Clinical F. Hoffmann-La Roche Ltd Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
AK-112 AK-112 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms; Neoplasm Metastasis Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase 1 Clinical Beijing Mali Biotechnology Co Ltd, Chengdu Yinhe Biomedicine Co Ltd Lymphoma, B-Cell Details
IBI318 IBI-318; LY-3434172; LY3434172 Phase 2 Clinical Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
Sasanlimab RN-888; PF-6801591; PF-06801591 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Pancreatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Bile Duct Neoplasms; Sarcoma; Prostatic Neoplasms; Urinary Bladder Neoplasms; Ovarian Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours Details
Recombinant humanized anti-PD-1 monoclonal antibody(Akeso Biopharma) AK-103; HX-008 Phase 3 Clinical Zhongshan Akeso Biopharma Co Ltd, Taizhou Hanzhong Biomedical Co Ltd, Hangzhou Hansi Biomedicine Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Thyroid Carcinoma, Anaplastic; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Melanoma; Adenocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
ONCR-177 ONCR-177 Phase 1 Clinical Oncorus Solid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Melanoma Details
CMAB-819 CMAB8-19 Phase 1 Clinical Sinomab Bioscience Ltd Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
GNR-051 GNR-051 Phase 1 Clinical Generium Pharmaceuticals Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
JTX-4014 (Jounce Therapeutics) JTX-4014 Phase 2 Clinical Jounce Therapeutics Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Spartalizumab PDR-001 Phase 3 Clinical Novartis Pharma Ag Sarcoma, Alveolar Soft Part; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Primary Myelofibrosis; Bone Marrow Diseases; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Chordoma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Persistent Fetal Circulation Syndrome; Stomach Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Leukemia; Leukemia, Myeloid; Head and Neck Neoplasms; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Thyroid Carcinoma, Anaplastic; Pancreatic Neoplasms; Neoplasms, Squamous Cell; Small Cell Lung Carcinoma; Myelodysplastic Syndromes; Digestive System Neoplasms; Multi Details
CA-170 CA-170; AUPM-170 Phase 2 Clinical Aurigene Solid tumours; Neoplasms Details
CC-90006 C-90006; CC-90006 Phase 1 Clinical Anaptysbio Autoimmune Diseases; Psoriasis Details
INCB-086550 INCB-086550 Phase 2 Clinical Incyte Corp Solid tumours; Carcinoma; Carcinoma, Renal Cell; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Balstilimab AGEN2034; RebmAb-700 Phase 2 Clinical Ludwig Institute For Cancer Research, Agenus Inc Hemangiosarcoma; Uterine Cervical Neoplasms Details
AK-104 AK-104 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Lymphoma, T-Cell, Peripheral; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Nasopharyngeal Carcinoma; Microsatellite Instability; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma Details
Retifanlimab INCMGA-0012; INCMGA-00012; MGA-012 Phase 3 Clinical Macrogenics Squamous Cell Carcinoma of Head and Neck; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Carcinoma, Renal Cell; Anus Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details
AMG-404 AMG-404 Phase 1 Clinical Amgen Inc Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms Details
CS-1003 CS-1003 Phase 3 Clinical Cstone Pharmaceuticals Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular Details
MEDI-0680 AMP-514; MEDI-0680 Phase 2 Clinical Medimmune Kidney Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell Details
BI-754091 BI-754091 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Solid tumours; Head and Neck Neoplasms; Rectal Neoplasms; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Cetrelimab JNJ-3283; JNJ-63723283 Phase 3 Clinical Johnson & Johnson Carcinoma, Transitional Cell; Multiple Myeloma; Urinary Bladder Neoplasms Details
HLX-10 HLX-10 Phase 3 Clinical Shanghai Henlius Biotech Co Ltd Solid tumours; Head and Neck Neoplasms; Liver Neoplasms; Hepatitis B, Chronic; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Microsatellite Instability; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
STW204单抗 STW-204 Phase 1 Clinical Suzhou Sitanwei Biological Technology Co Ltd Solid tumours Details
Pidilizumab CT-011; MDV-9300 Phase 2 Clinical Curetech Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Multiple Myeloma; Lymphoma, Follicular; Prostatic Neoplasms; Hepatitis C; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Glioma; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) Phase 1 Clinical Hengrui Yuanzheng Biotechnology Co Ltd Solid tumours; Stomach Neoplasms Details
Recombinant human anti-PD-1 monoclonal antibody(Yiyi Health Technology) Phase 1 Clinical Shanghai Yunyi Health Technology Development Co Ltd Neoplasms Details

This web search service is supported by Google Inc.

totop